Program
SAL003
A development code. Also written as “SAL003 140 mg”, “SAL003 140mg+Atorvastatin” and “SAL003 420mg+Atorvastatin”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias, led by Shenzhen Salubris Pharmaceuticals.
Furthest: phase 3, since Nov 19, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 30 open or running | phase 3since Nov 19, 2025 | Nov 19, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2025First study: phase 3 study in HyperlipidemiasFirst studyNCT07253584 · 720 enrolled · China
- Dec 1, 2025Phase 2 study in HypercholesterolemiaNCT07278830 · 214 enrolled · China
- Dec 7, 2025Phase 3 study in HyperlipidemiasNCT07295418 · 618 enrolled · China
TargetBeta
PCSK9 →read by rule
“This is a Phase 3 study to evaluate the efficacy and safety of SAL003, a fully human monoclonal antibody against PCSK9, as monotherapy in Chinese participants with hypercholesterolemia and mixed dyslipidemia.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07295418Hyperlipidemias · China | 3 | Completed | Apr 22, 2025 | 618 |
| NCT07278830Hypercholesterolemia · China | 2 | Completed | May 24, 2024 | 214 |
| NCT07253584Hyperlipidemias · China | 3 | Completed | Jun 23, 2025 | 720 |
How it is read
Names in the registry
- “SAL003 140 mg”, 2 entries
- “SAL003 140mg+Atorvastatin”, 1 entry
- “SAL003 420mg+Atorvastatin”, 1 entry
Codes read as this program: SAL003.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 2 studies
- Hyperlipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.